Here are the 10-K annual reports from AnaptysBio, Inc. (ANAB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ANAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANAB filings page.
AnaptysBio, Inc. filed Amendment No. 1 to its annual report to add detailed disclosures on directors, executive officers, governance, compensation and ownership, instead of using a separate proxy statement. The filing updates board class composition following director departures so that six directors are evenly split across three staggered classes, and confirms committee memberships and independence.
The amendment describes 2025 non‑employee director compensation, including cash retainers and equity grants, and outlines a pay‑for‑performance program for executives that combines salary, annual bonuses and stock‑based incentives such as options, RSUs and performance stock units tied to ambitious share‑price hurdles. It also explains severance and change‑in‑control protections, a clawback policy, and the impact of the April 2026 spin‑off of First Tracks Biotherapeutics, including the CEO’s consulting arrangement and equity award treatment.
AnaptysBio, Inc. is a clinical-stage biotechnology company developing antibody therapies for autoimmune and inflammatory diseases. Its wholly owned pipeline includes rosnilimab, which delivered statistically significant Phase 2b results in moderate-to-severe rheumatoid arthritis, plus ANB033 in Phase 1b trials for celiac disease and eosinophilic esophagitis, and ANB101 in a Phase 1 trial targeting BDCA2 on plasmacytoid dendritic cells.
The company also earns milestones and royalties from partnered antibodies. GSK’s PD‑1 drug Jemperli generated $1.1 billion in 2025 sales, up from $598.0 million in 2024. Vanda holds global rights to imsidolimab for generalized pustular psoriasis, with a BLA accepted by the FDA and a target action date of December 12, 2026.
In September 2025, AnaptysBio’s board approved plans to pursue a separation into two independent public companies, one focused on managing Jemperli and imsidolimab financial collaborations and one focused on advancing its clinical immunology pipeline. The separation is expected in the second quarter of 2026, subject to board approval and SEC registration effectiveness.